Filed Pursuant to Rule 433
Issuer Free Writing Prospectus
Dated February 5, 2014
Relating to Preliminary Prospectus Dated January 24, 2014
Registration Statement No. 333-193158
Registration Statement No. 333-193757



## 5,400,000 Ordinary Shares

## **Pricing Term Sheet**

Ordinary shares offered 5,400,000 ordinary shares

Underwriters' option 810,000 ordinary shares

Initial public offering price \$17.00 per ordinary share

Net Proceeds We estimate that the net proceeds from our issuance and sale of 5,400,000 ordinary shares in this

offering will be approximately \$81.9 million, based on the initial public offering price of \$17.00 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional shares, we estimate that the

net proceeds from this offering will be approximately \$94.7 million.

NASDAQ Global Select Market Symbol QURE

Potential purchase by Existing Principal

Shareholders

As Adjusted Financial Data

713 / Tajustea I manetai Data

Dilution

Certain of our existing shareholders have indicated an interest in purchasing an aggregate of 1,239,706 ordinary shares in this offering at the initial public offering price, for an aggregate purchase price of approximately \$21.1 million, including the following principal existing shareholders: Forbion: approximately \$1.0 million or 58,823 ordinary shares; Gilde: approximately \$1.35 million or 79,412 ordinary shares, and Coller: approximately \$17.5 million or 1,029,412 ordinary shares. However, because indications of interest are not binding agreements or commitments to purchase, these stockholders may determine to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering.

Giving effect to this offering, as well as the receipt of approximately €16 thousand in connection with option exercises in November 2013, our as adjusted balance sheet data as of September 30, 2013 would have been as follows (in thousands):

Cash and cash equivalents	€	92,667
Total debt		8,456
Shareholders' equity:		
Ordinary shares		879
Share premium		204,712
Other reserves		5,924
Accumulated deficit		(138,953)
Total shareholders' equity		72,562
Total capitalization	€	81,018

Giving effect to this offering, our pro forma net tangible book value as of September 30, 2013 would have been \$88.8 million, or \$5.05 per ordinary share, giving effect to the 5-for-1 consolidation of our ordinary shares effected on January 31, 2014. This represents an immediate increase in pro forma net tangible book value per share of \$4.55 to existing shareholders and immediate dilution of \$11.95 in pro forma net tangible book value per ordinary share to new investors purchasing ordinary shares in this offering.

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, or by email at Prospectus\_Department@Jefferies.com, or by phone at 877-547-6340; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at